PubMed Health⌕ Search

Biomedical subjects

G D Resnick

Publications and source records attributed to G D Resnick.

7 recordsLinked to original sources
PubMed1997

Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.

A recently completed Eastern Cooperative Oncology Group trial, E1684, has shown that adjuvant therapy with high-dose recombinant interferon alfa-2b (rIFN-alpha 2b) has a significant impact on relapse-free and overall survival in melanoma patients at high risk of recurrence. Adjuvant rIFN-alpha 2b increased the median overall survival to 3.82 years in the treatment group compared with 2.78 years with observation and yielded a 5-year survival rate of 46% versus 37% with observation. This is the first adjuvant therapy to significantly extend survival in this patient population (P = .0023, one-sided). The response to therapy was greatest among those patients with clinical evidence of nodal metastasis. The toxicity associated with this regimen was substantial but tolerable. Approximately 78% of patients treated with rIFN-alpha 2b experienced grade 3 or greater toxicity, and dose modifications were required for 37% and 36% of patients in the induction or maintenance phase, respectively. Quality-of-life-adjusted survival analysis has shown that, despite the toxicity associated with rIFN-alpha 2b therapy, the quality-of-life-adjusted time gained with rIFN-alpha 2b therapy outweighs the reduced quality of life associated with treatment toxicity and relapse. These data support the use of high-dose rIFN-alpha 2b as adjuvant therapy in melanoma patients at high risk of recurrence.

Chemotherapy, Adjuvant↗
PubMed1995

Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.

BACKGROUND: Recent data have suggested that there are no differences among various anthracycline-based chemotherapy regimens [including cyclophosphamide, vincristine, methotrexate, and prednisone (CHOP), methotrexate, calcium leucovorin, bleomycin, doxorubicin, cyclophosphamide, and dexamethasone (m-BACOD), methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B), and cyclophosphamide, doxorubicin, etoposide, prednisone, cytosine arabinoside, bleomycin, vincristine, methotrexate, and calcium leucovorin (PROMACE-cyta-BOM)] in patients with diffuse aggressive lymphomas. Because outcome appears to depend on certain prognostic factors, risk groups can be identified. Therefore, these prognostic factors were examined for their correlations with survival, time-to-treatment failure (TTF), and disease free survival (DFS) in a group of patients with diffuse aggressive non-Hodgkin's lymphoma who were treated on a single randomized trial with either CHOP or m-BACOD. METHODS: From July 1984 to January 1988, 392 patients with diffuse large cell or diffuse mixed non-Hodgkin's lymphoma were enrolled in an Intergroup study and were randomly assigned to treatment with CHOP or m-BACOD chemotherapy. Of these, 325 were eligible for response, toxicity, and survival analysis, and the results were reported. The survival and TTF results now have been updated. The 286 patients who had lactic dehydrogenase (LDH) data available at study entry were analyzed for prognostic features according to the International Index criteria and using Martingale Residuals for proportional hazards regression. RESULTS: There were no differences in survival, TTF, and disease free survival between groups of patients treated with either CHOP or m-BACOD. In addition, analysis using the International Index criteria confirmed that patients in the lower risk groups had better outcome than patients in the higher risk groups (5-year survival was 56 and 58% for low and low/intermediate risk groups, respectively, and 37% and 31% for high/intermediate and high risk groups, respectively). There were, however, no differences in survival, disease free survival, or TTF within any risk group when treatment with CHOP or m-BACOD were compared. In addition, analysis using Martingale residuals for proportional hazards regression identified LDH level (> 3 x normal) as an important prognostic factor that was not captured by the International Index. Thus, 5-year survival was 57% if LDH was normal or below, 42% if LDH was 1-3 x normal, and 21% if LDH was > 3 x normal. CONCLUSION: In patients with advanced diffuse large cell or diffuse mixed non-Hodgkin's lymphoma, there are no differences in outcome that can be attributed to treatment with CHOP vs. m-BACOD; this holds for any prognostic group identified by the International Index. However, the level of LDH at time of study entry is an important prognostic factor that is predictive of survival and may help to identify candidates for future clinical trials.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1992

Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma.

BACKGROUND: In 1984, the Eastern Cooperative Oncology Group began a randomized controlled clinical trial of patients with advanced (stage III or IV) diffuse mixed or diffuse large-cell lymphoma to determine whether complete-remission rates, survival, and toxicity differed when patients were treated with a chemotherapeutic regimen containing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), as compared with a regimen containing bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone, methotrexate, and leucovorin (m-BACOD). METHODS: From July 1984 through January 1988, 392 patients were enrolled, 325 of whom (83 percent) were eligible for the analysis and capable of being evaluated. The extent of disease was defined according to standard staging techniques, including bilateral bone-core biopsies in 88 percent of patients. Randomization was stratified according to age (< 60 or > or = 60 years), performance status (0, 1, or other), stage (III or IV), and histologic presentation (diffuse mixed or diffuse large-cell lymphoma). RESULTS: After a median follow-up of four years, there were no significant differences in rates of complete remission, time to treatment failure, disease-free survival, or overall survival in the patients treated with CHOP as compared with those treated with m-BACOD. However, there was more severe and life-threatening pulmonary, infectious, and hematologic toxicity associated with the m-BACOD regimen. In an attempt to measure the importance of dose intensity in the 325 patients who could be analyzed, we retrospectively calculated dose intensity (measured in milligrams per square meter of body-surface area per week) and normalized dose intensity (defined as a percentage of the prescribed dose) for all drugs. The median normalized dose intensity for both cyclophosphamide and doxorubicin was found to be greater in the patients treated with CHOP than in those treated with m-BACOD. CONCLUSIONS: For patients with stage III or IV diffuse mixed or diffuse large-cell lymphoma, CHOP is superior to m-BACOD, but the role of dose intensity is not yet clear.

Age Factors↗
PubMed1981

Reed-Sternberg cells in Hodgkin's disease contain fibronectin.

Reed-Sternberg cells in the lymph nodes from five patients with Hodgkin's disease were studied. Indirect immunofluorescence on fixed sections with a monospecific anti-serum to fibronectin revealed abundant cytoplasmic fibronectin in approximately 90% of the Reed-Sternberg cells. In addition, the cells were shown by immunofluorescence to contain polyclonal IgG; however, factor VIII antigen, albumin, fibrinogen, alpha-2-macroglobulin, anti-thrombin III, and ceruloplasmin were not present. The abundant cytoplasmic fibronectin suggests that Reed-Sternberg cells are derived from tissue macrophages.

Animals↗
PubMed1973

On the virulence of group A streptococci: evidence for virulence factors other than M-protein and capsule.

Group A streptococci from parent cultures (PC) of six different serotypes were selected by rotation with human blood (RHB) or by serial passage via intraperitoneal inoculation in mice (MP). M-protein content of PC, RHB and MP streptococci of each serotype was determined in quintuplicate by radial immunodiffusion against type-specific antisera. Hyaluronic acid content was determined in quintuplicate colorimetrically after treatment of streptococci with hyaluronidase. Data were subjected to variance analysis. LD(50) for mice of PC, RHB and MP streptococci, inoculated intraperitoneally, was also determined. It was observed that MP streptococci virulent for mice were rich in M-protein and hyaluronic acid. However, RHB streptococci of M-protein and hyaluronic acid content similar to MP streptococci were not virulent for mice. This dichotomy with respect to mouse virulence infers the existence of as yet unidentified streptococcal virulence factors, in addition to M-protein and capsule.

Analysis of Variance↗